Volume 10, Number 6—June 2004
Dispatch
SARS and Common Viral Infections
Table 2
PCR (N = 151) |
Culture (N = 154) |
Serologic testingb (N = 78) |
|
---|---|---|---|
n (%) | n (%) | n (%) | |
Influenza A | 27 (18)c | 9 (6) | 4 (5)d |
Influenza B | 1 (1) | 1 (1) | 1 (1)d |
Respiratory syncytial virus | 5 (3) | 1 (1) | 1 (1)d |
Parainfluenza virus types 2–4 | 6 (5) | 5 (4) | 0 |
Human metapneumovirus | 11 (7) | 0 | ND |
Coronavirus OC43 | 1 (1) | 0 | ND |
Coronavirus 229E | 0 | 0 | ND |
Parainfluenza virus type 1 | 0 | 0 | ND |
Adenovirus | 0 | 0 | 1 (1)d |
Picornavirus | 12 (8) | 0 | ND |
Mycoplasma pneumoniae | 0e | ND | 3 (4)c |
Chlamydia spp. | 0e | ND | 1 (1) |
SARS-CoV | 0 | 0 | 2 (3) |
Total positive | 63 (42) | 16 (10) | 13 (17) |
aND, not done; SARS-CoV, severe acute respiratory syndrome–associated coronavirus.
bMeasured as a significant rise in immunoglobulin (Ig) G in paired serum samples for all specimens except one positive for M. pneumoniae IgM.
cSpecimens from one case-patient positive for influenza A (by PCR and culture) were also positive for M. pneumoniae IgM.
dOne specimen negative by culture.
eChlamydia pneumoniae PCRs were performed retrospectively only on specimens from patients with serologic evidence of M. pneumoniae (n = 3) and Chlamydia spp. (n = 1) infection.
Page created: February 22, 2011
Page updated: February 22, 2011
Page reviewed: February 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.